Navigation Links
California Oncology Group Uses New Technology to Choose Best Cancer Treatment
Date:4/1/2011

NASHVILLE, Tenn., April 1, 2011 /PRNewswire/ -- Imagine the benefits if there was technology that pinpointed exactly which chemotherapy drugs work best in fighting each individual's type of cancer. No more guessing. No more trial and error. The good news is that such lifesaving technology is on its way to becoming reality.

Clinical trials involving 38 patients at Wilshire Oncology Medical Group are yielding positive results. Wilshire has several offices in Southern California including Pomona, Rancho Cucamonga, Glendora, West Covina, Pasadena and La Verne.

Rancho Cucamonga resident Yvonne Cardinale has been a patient with Wilshire Oncology for about 18 years, being first diagnosed with an aggressive breast cancer in October 1993. "I went through five months of traditional chemotherapy and a stem cell transplant," Cardinale said. "Then it came back. I was re-diagnosed in February 2008 when it was found in the lining of my lung."

Dr. Linda Bosserman, Cardinale's Pomona-based doctor, is also president of Wilshire Oncology Medical Group. Bosserman approached Cardinale, now 58, with the idea of committing to a clinical trial of a chemosensitivity test or assay. Cardinale agreed.

Cancerous fluid was taken from Cardinale's lung and sent to DiaTech Oncology Corp., a private laboratory based in Nashville, Tennessee, for testing. DiaTech uses a microculture kinetic (called MiCK) assay test to help predict treatment outcomes and to help decide which chemotherapy would be best for specific patients. Various forms of chemotherapy were tried on Cardinale's cancer cells.

"I was given the two most effective drugs that worked on my cancer," she said. "I felt because of this study I had a real advantage. The drugs worked well, and I feel good." Cardinale, whose mother is also a breast cancer survivor, will take her last dose of chemotherapy this month.

"What this test does is expose cancer cells to various chemotherapy drugs in the lab. We just need some biopsied cancer cells or - if we're dealing with leukemia - blood," said Dr. Swapnil Rajurkar, lead medical investigator for Wilshire. "I get the results back from the lab saying, 'These drugs are likely to work and these are not.'" Rajurkar explained that breast cancer has about 10 approved drug treatments. It's up to the individual oncologist, depending on what's known about the patient's condition and the doctor's experience, to decide which treatments are used first.

"This is invaluable information," Bosserman said. "One of our biggest challenges is when we treat people we go by guidelines, but individual patients' tumors are unique and personal. By being able to find out what chemotherapies the patients might be responsive to, and what they are not going to respond to, we can save them weeks and months of getting treatment that is not going to help them - all of which have side effects and will decrease their quality of life.

"We're actually going into active treatment with one of the health plans where they're going to pay for this test ahead of time in patients and keep track of this additional data on how patients do," Bosserman said. "This means that for future patients, if the test says the drug will work, it will work."

On the flip side, if the test reveals a drug is useless against an individual's cancer, that patient would not have to go through an ineffective treatment. "This information really helps patients make decisions, especially if facing very advanced cancer where, we know a lot of times, those last-ditch treatments don't help patients and take up their valuable days of life," she said. "It really helps patients realize that they are not giving up hope, but can choose aggressive palliative care rather than treatment that really won't help them. The test offers the promise of adding more information to help guide better treatment decisions for patients."

DiaTech Life Sciences is a privately held clinical pathology laboratory working to help oncologists and their patients deal with the devastating effects of cancer. The MiCK assay is the only test available that measures the chemotherapeutic drug effect for a specific patient, both kinetically and accurately. The MiCK assay has also been used to determine the effectiveness of new drugs in preclinical trials for the pharmaceutical industry.

Contact:

Steve Latimer
1-866-556-5356  
info@diatechoncology.com
http://www.diatech-oncology.com  

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE DiaTech Oncology
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Surgeons at University of California San Diego Perform 1st TRAM Flap Procedure in an International Multi-Center Study Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
2. Encinitas Nursing and Rehabilitation Center First in Southern California to Deploy Voice Technology for Outcomes-Based Care
3. MEPS Real Times New RFID Drug Management System Provides Critical Error Solution for California Hospital
4. Boehringer Ingelheim to Purchase Amgens Fremont (California) Facility
5. New Program for Medicare Beneficiaries Will Mean Major Changes Effective January 1, 2011 - California
6. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
7. NeoStem to Present at Cell Therapy Industry Summit to be held on November 3-5, 2010 in Carlsbad, California
8. ICAP Ocean Tomo to Auction 7 Exclusive Licenses from Lawrence Livermore National Laboratory at Fall Auction November 11th in Napa, California
9. AstraZeneca and the Sacramento County Pharmacy Provide Free Medicines to Eligible California Patients
10. Largest Study of Melanoma in US Hispanics Reveals California Population in Need of Targeted Prevention Efforts
11. BioSpace Showcases Southern Californias Growing Life Science Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
(Date:2/24/2017)... , Feb. 23, 2017 Report analyzes the worldwide ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin America ... are provided for the period 2015 through 2022. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market ... companies have joined forces, resulting in the founding of Pharma To ... Pharma To Market are pleased to announce their expansion into ... in Singapore . The company are delighted to ... Co-Director of the Singapore based entity. Joelle ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Elisa Guajardo Carothers is not your typical author. She went ... become a nun. Now, she writes about God, when she isn’t swimming as a performing ... AD, Here is BS! (Before Satan),” she offers a comedic look at the dysfunctions of ...
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate smart media center ... brings songs, movies, TV shows and much more apps for user exploration. Its innovative ... immersive view of 1280 x 720 provides crisp images with remarkable clarity and color. ...
(Date:2/27/2017)... BC (PRWEB) , ... February 27, 2017 , ... ... drug rehabilitation and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ ... to its team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to ...
(Date:2/27/2017)... , ... February 27, 2017 , ... New Jersey ranks ... among all types and genders. And the need for advanced services is growing. ... its top-rated cancer care program, in collaboration with their non-profit partners in their fight ...
(Date:2/26/2017)... ... 2017 , ... This is an extension of airmid’s scope ... ISO/IEC 17025:2005 INAB accredited for Der p 1 (house dust mite allergen) & ... standard that sets out requirements for the technical competence of testing and calibration ...
Breaking Medicine News(10 mins):